

NEWSLETTER

Volume 8, June 2024

UPDATES IN BRIEF FROM JANUARY–JUNE 2024.

ANNOUNCEMENT

- We are pleased to announce that National Cancer Grid (NCG) has approved Expansion of Hematology Cancer Consortium Registry in India (HCCE) project for funding.
- HCC APL22 DOSA study has been initiated and the first patient has been enrolled by CMC, Vellore

NEW INSTITUTIONAL PARTNERS



Amrita Institute of Medical Sciences
(AIMS), Kochi



MVR Cancer Centre and
Research Institute
(MVRCCRI), Calicut



Tata Medical Center, Kolkata

MEMBERSHIP UPDATE

30 - INSTITUTIONAL PARTNERS

635 - INDIVIDUAL MEMBERS
CONSULTANTS, PHYSICIANS, NURSES,
DATA ENTRY OPERATORS AND PATIENTS

HCC DISEASE WORKING GROUP

AML/APML

ALL

Lymphoma

CML

MDS/MPN

Priority areas:

- 1.AML Registry CRF update under process
- 2.Standardization of Azacytidine and Venetoclax protocol
3. To develop prospective research protocols

Priority areas:

- 1.ALL Registry CRF update under process
- 2.To develop prospective research protocols

Priority areas:

- 1.LYM Registry CRF update under process
- 2.To develop prospective research protocols

Priority areas:

- 1.CML Registry CRF update under process
- 2.To develop prospective research protocols

Priority areas:

- 1.MPN (myeloproliferative neoplasms) Registry CRF development under process

EDUCATION & TRAINING

PATIENT ADVOCACY SESSION

HCC's Patient Advocacy Group has been formed in January 2023 and the team has launched an online support group for patients, survivors and caregivers.

The Patient Support Group meetings are held on third Saturday of every month at 11.00am.

So far we have conducted twelve patient support group sessions.

We are deeply grateful to all the experts for dedicating their time and conducting the sessions for patients and caregivers

Support group meeting topic since January 2024:

| | |
|--|---|
| <p>Topic: CAR T cell therapy as a treatment option for blood cancer Speaker: Dr Hasmukh Jain Professor Medical Oncology Tata Memorial Hospital</p> |  |
| <p>Topic: Strategies for managing emotions during treatment of blood cancer Speaker: Dr Nivedita Chalill Counsellor and Arts Based Therapist Founder, ARTH</p> |  |
| <p>Topic: Care for patients of blood cancer Speaker: Dr Punit Jain Consultant Hematologist, Program Coordinator, BMT physician Apollo Hospital</p> |  |
| <p>Topic: Defining Survivorship in blood cancer Speaker: Dr Maya Prasad Professor Pediatric Oncology, Tata Memorial Hospital</p> |  |
| <p>Topic: Maintaining hygiene during the treatment of blood cancer Speaker: Ms. Sindhu Nair Nursing Superintendent, Tata Memorial Hospital</p> |  |

EDUCATION & TRAINING

NURSING WEBINARS

HCC nurses group had initiated an education program to enhance knowledge since January 2021.

Webinars are held on the last Tuesday of every month at 3.00pm.

So far we have conducted thirty-one nursing webinars.

Thank you, team! We are deeply grateful to all the experts for dedicating their time and conducting the sessions for nurses.

Nursing Webinars conducted since January 24:

| | |
|--|---|
| <p>Topic: Nursing care for older adults with hematological malignancies Speaker: Mrs Sathyabala Ramachandran Nursing Educator and Tutor Adyar Cancer Institute (WIA)</p> |  |
| <p>Topic: Nursing management of children diagnosed with Leukemia Speaker: Dr Anita David Professor and HOD, Dept of Pediatric Nursing SRIHER, Chennai</p> |  |
| <p>Topic: Cytotoxic Agents: Play Safe, Play Smart Speaker: Mrs Mita Roy Chowdhury Msc Child Health, Nursing, Former Clinical Nurse Specialist TMC Kolkata, Senior Manager, Narayana Super Speciality Hospital, Kolkata</p> |  |
| <p>Topic: Nursing Perspective: Acute GVHD and its Management Speaker: Mrs Abhijah Princy, Associate Professor, Hematology Nursing Department Christian Medical College, Vellore</p> |  |
| <p>Topic: Role of Nurses in Venous Occlusive Disease (VOD) management Speaker: Ms Monima Baruah, Staff nurse at the Stem Cell Transplantation unit, Guwahati Medical College and Hospital</p> |  |

DATA ENTRY OPERATOR TRAINING (DEO)

We are assessing and identifying areas where the DEO's need training and accordingly offering customized training session.

Training recordings are available at: <https://hemecancer.org/training-module.php>

DEO Training Session conducted since January 2024:

Topic: HCC DEO Training Session- AML, ALL, Lymphoma and CML

Speaker: Dr Manju Sengar,
Professor of Medical Oncology,
Tata Memorial Centre



ONGOING CLINICAL TRIALS

Study Title: Phase III open labeled randomized controlled study to evaluate the optimal dose of all-trans retinoic acid in the treatment of low and intermediate risk acute promyelocytic leukemia. (HCC-APL22 DOSA Study)

- CTRI No.: CTRI/2023/09/057990
- Study design: Phase III open labeled Randomized Control Trial
- Sample size: 280 patients (140 patients in each arm)
- Study duration: 3 years
- Indication: Patients with newly diagnosed with Acute Promyelocytic Leukemia and age more than 15 years at diagnosis.
- Update: First patient enrolled in the study by Christain Medical College, Vellore

Study Title: A phase III RCT comparing AVD + low dose nivolumab versus ABVD using risk -adapted strategy in newly diagnosed advanced stage classical Hodgkin Lymphoma (LoNAH Study)

- CTRI Registration no.: CTRI/2024/03/063942
- Study design: Open Label, Randomized, Parallel Group, Active Controlled Trial
- Sample size: 280 patients (140 patients in each arm)
- Study duration: 3 years
- Indication: Patients with newly diagnosed advanced stage HL with a PET scan done within previous one month and age above 12 years
- Update: Patient enrolment has started and 5 patients have been enrolled by Christian Medical College, Vellore

Cont..

Ongoing Clinical Trials

Study Title: A phase III randomized study to compare a risk-stratified and response-adapted strategy to ABVD regimen in adolescents and adults with advanced-stage Hodgkin lymphoma. (ABVD Hodgkin's Study)

- CTRI Registration no.: CTRI/2020/12/030132
- Study design: Open-label, Phase III randomized study, comparison of two standard-of-care approaches
- Sample size: 200 patients
- Study duration: 4 years accrual, 3 years follow-up since last enrolled patient and 10 years for long-term follow-up phase since the last patient is enrolled.
- Update: 194 patients enrolled in total

Study Title: Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (HCC pRISM-S)

- CTRI Registration No: CTRI/2020/07/026450
- Update: Enrolment is complete, 3 years follow up data collection is going on; Source data verification and data validation is completed; Data analysis and manuscript work is on-going; Initial data was presented as an abstract in ASH 2022

Study Title: COVID-19 Hematological Cancers Registry of India (CHCRI Study)

- Study Design: Observational [Patient Registry]
- Observational Model: Case-Only
- Time Perspective: Prospective and Retrospect
- Update: Enrolment is complete, 5-year follow-up data collection is going on; Data validation is in progress; Analysis will be done after completion of long term follow up; Initial data has been published in Blood Cancer Journal

STUDY STATUS

HCC has completed 9 observational studies and 1 prospective study till date

HCC EXPRESSES HEARTFELT GRATITUDE TO THE NATIONAL CANCER GRID FOR THEIR UNWAVERING SUPPORT TOWARDS THE REGISTRY, AS WELL AS TO INDIVIDUAL AND CORPORATE SUPPORTERS FOR THEIR GENEROUS CONTRIBUTIONS

INDIVIDUALS AND INSTITUTIONS WITH AN INTEREST IN HEMATOLOGICAL MALIGNANCIES CAN BECOME MEMBERS, REGISTER : [HTTP://HEMECANCER.ORG/MEMBERSHIP.PHP](http://hemecancer.org/membership.php)

